Antiepileptic drug monotherapy versus polytherapy: Pursuing seizure freedom and tolerability in adults

Current Opinion in Neurology

Volumn 25, Issue 2, 2012, Pages 164-172

  Stephen, Linda J ^a   Brodie, Martin J ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

Antiepileptic drugs; Efficacy; Interactions; Side effects; Tolerability

Indexed keywords

CLINICAL EVALUATION; COST EFFECTIVENESS ANALYSIS; EPILEPSY; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HUMAN; MEDICAL PRACTICE; NEUROIMAGING; NEUROPHYSIOLOGY; NEUROSURGERY; QUALITY OF LIFE; REVIEW; SEIZURE; TREATMENT OUTCOME;

ANTICONVULSANTS; CHEMISTRY, PHARMACEUTICAL; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; LEARNING DISORDERS; PATIENT COMPLIANCE; SEIZURES; TREATMENT OUTCOME;

EID: 84859783153     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e328350ba68     Document Type: Review

References (79)

1. Sander JW. The epidemiology of epilepsy revisited. Curr Opin Neurol 2003; 16:165-170. (Pubitemid 36521202)
2. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342:314-319. (Pubitemid 30075244)
3. Mohanraj R, Brodie MJ. Diagnosing refractory epilepsy: response to sequential treatment schedules. Eur J Neurol 2006; 13:277-282.
4. Brodie MJ, Barry SJ, Bamagous GA, et al. Patterns of treatment response in newly diagnosed epilepsy. Neurology (in press).
5. Löscher W, Schmidt D. Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia 2011; 52:657-678.
6. Berg AT, Lanfitt J, Shinnar S, et al. How long does it take for partial epilepsy to become intractable? Neurology 2003; 60:186-190. (Pubitemid 36152006)
7. Schiller Y. Seizure relapse and development of drug resistance following long-term remission. Arch Neurol 2009; 66:1233-1239.
8. Neligan A, Bell GS, Sander JW, Shorvon SD. How refractory is refractory epilepsy? Patterns of relapse and remission in people with refractory epilepsy. Epilepsy Res 2011; 96:225-230.
9. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010; 51:1069-1077.
10. Stephen LJ, Forsyth M, Kelly K, Brodie MJ. Antiepileptic drug combinations: have newer agents altered clinical outcomes? Epilepsy Res 2011. [Epub ahead of print]
11. Kwan P, Brodie MJ. Combination therapy in epilepsy. When and what to use. Drugs 2006; 66:1817-1829. (Pubitemid 44584005)
12. French JA, Faught E. Rational polytherapy. Epilepsia 2009; 50 (suppl 8):63-68.
13. St Louis EK. Truly "rational" polytherapy: maximising efficacy and minimising interactions, drug load and adverse effects. Curr Neuropharmacol 2009; 7:96-105.
14. Gidal BE. Do new antiepileptic drugs with novel mechanisms of action suggest reconsideration of rational polypharmacy? US Neurology 2010; 6:70-76.
15. Brodie MJ, Covanis A, Gil-Nagel A, et al. Antiepileptic drug therapy: does mechanism of action matter? Epilepsy Behav 2011; 21:331-341.
16. Reynolds EH, Shorvon SD. Monotherapy or polytherapy for epilepsy? Epilepsia 1981; 22:1-10. (Pubitemid 11190150)
17. Schmidt D. Two antiepileptic drugs for intractable epilepsy with complex-partial seizures. J Neurol Neurosurg Psychiatry 1982; 45:1119-1124. (Pubitemid 13166258)
18. Shorvon SD, Reynolds EH. Reduction in polypharmacy for epilepsy. Br Med J 1979; 2:1023-1025. (Pubitemid 10194418)
19. Schmidt D. Reduction on two-drug therapy in intractable epilepsy. Epilepsia 1983; 24:368-376. (Pubitemid 13106557)
20. Deckers CL, Hekster YA, Keyser A, et al. Monotherapy versus polytherapy for epilepsy: a multicenter double-blind randomized study. Epilepsia 2001; 42:1387-1394. (Pubitemid 33140612)
21. Beghi E, Gatti G, Tonini C, et al. Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial. Epilepsy Res 2003; 57:1-13. (Pubitemid 38045463)
22. Kwan P, Brodie MJ. Epilepsy after the first drug fails: substitution or add-on? Seizure 2000; 9:464-468.
23. Mohanraj R, Brodie MJ. Pharmacological outcomes in newly diagnosed epilepsy. Epilepsy Behav 2005; 6:382-387. (Pubitemid 40468428)
24. Perucca E, Tomson T. The pharmacological treatment of epilepsy in adults. Lancet Neurol 2011; 10:446-456.
25. Brodie MJ, Yuen AW. Lamotrigine substitution study: evidence for synergism with sodium valproate? Epilepsy Res 1997; 26:423-432. (Pubitemid 27146300)
26. Saké J-K, Hebert D, Isojarvi J, et al. A pooled analysis of lacosamide clinical trial data grouped by mechanisms of action of concomitant antiepileptic drugs. CNS Drugs 2010; 24:1055-1068.
27. Brodie MJ, Sills GJ. Combining antiepileptic drugs: rational polytherapy? Seizure 2011; 20:369-375.
28. Marson AG, Al-Kharusi A,Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007; 369: 1016-1026. (Pubitemid 46436125)
29. Elterman RD, Shields WD, Mansfield KA, et al. Randomized trial of vigabatrin in patients with infantile spasms. Neurology 2001; 57:1416-1421. (Pubitemid 32995722)
30. Sazgar M, Bourgeois FD. Aggravation of epilepsy by antiepileptic drugs. Pediatr Neurol 2005; 33:227-234. (Pubitemid 41382499)
31. Kwan P, Schachter S, Brodie MJ. Drug-resistant epilepsy. N Eng J Med 2011; 365:919-926.
32. Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia 2007; 48:1223-1244. (Pubitemid 47063067)
33. Messenheimer J, Mullens EL, Giorgi L, Young F. Safety review of adult clinical trial experience with lamotrigine. Drug Saf 1998; 18:281-296. (Pubitemid 28177292)
34. Johannessen CU, Jahnnessen SI. Valproate: past, present, and future. CNS Drug Rev 2003; 9:199-216. (Pubitemid 36903892)
35. Gidal B. Carbamazepine hypersensitivity: progress toward predicting the unpredictable. Epilepsy Curr 2011; 11:189-191.
36. Landmark CJ. Antiepileptic drugs in nonepilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs 2008; 22:27-47.
37. Kaufman KR. Antiepileptic drugs in the treatment of psychiatric disorders. Epilepsy Behav 2011; 21:1-11.
38. Garcia-Borreguero D, Larrosa O, Williams AM, et al. Treatment of restless legs syndrome with pregabalin: a double-blind, placebo-controlled study. Neurology 2010; 74:1897-1904.
39. Kushida CA, Becker PM, Ellenbogen AL, et al. Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS. Neurology 2009; 72:439-446.
40. Ben Menachem E. Weight issues for people with epilepsy: a review. Epilepsia 2007; 48 (suppl 9):42-45.
41. Hu X, Wang J, Dong W, et al. A meta-analysis of polycystic ovary syndrome in women taking valproate for epilepsy. Epilepsy Res 2011; 97:73-82.
42. Wroe S. Zonisamide and renal calculi in patients with epilepsy: how big an issue? Curr Med Res Opin 2007; 23:1765-1773. (Pubitemid 47300374)
43. Loring DW, Marino S, Meador KJ. Neuropsychological and behavioural effect of antiepilepsy drugs. Neuropsychol Rev 2007; 17:413-425. (Pubitemid 350231552)
44. Brodie MJ, Pellock JM. Taming the brain storms: felbamate updated. Lancet 1995; 346:918-919.
45. Thadani H, Deacon A, Peters T. Diagnosis and management of porphyria. Br Med J 2000; 320:1647-1651. (Pubitemid 30364637)
46. Stephen LJ, Brodie MJ. Pharmacotherapy of epilepsy. Newly approved and developmental agents. CNS Drugs 2011; 25:89-107.
47. Lammers MW, Hekster YA, Keyser A, et al. Monotherapy or polytherapy for epilepsy revisited: a quantitative assessment. Epilepsia 1995; 36:440-446.
48. Deckers CL, Hekster YA, Keyser A, et al. Reappraisal of polytherapy in epilepsy: a critical review of drug load and adverse effects. Epilepsia 1997; 38:570-575. (Pubitemid 27199912)
49. Deckers CL, Hekster YA, Keyser A, et al. Drug load in clinical trials: a neglected factor. Clin Pharmacol Ther 1997; 62:592-595. (Pubitemid 28068062)
50. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2011. Available on http://www.whocc.no/atc-ddd-index/. [Accessed 1 November 2011]
51. Luszczki JJ, Czuczwar SJ. Preclinical profile of combinations of some second-generation antiepileptic drugs: an isobolographic analysis. Epilepsia 2004; 45:895-907. (Pubitemid 39062811)
52. Cereghino JJ, Brock JT, Van Meter JC, et al. The efficacy of carbamazepine combinations in epilepsy. Clin Pharmacol Ther 1975; 18:733-741.
53. Deckers CL, Czuczwar SJ, Hekster YA, et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 2000; 41:1364-1374.
54. Pisani F, Oteri G, Russo MF, et al. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia 1999; 40:1141-1146. (Pubitemid 29372631)
55. Rowan AJ, Meijer JW, de Beer-Pawlikowski N, van der Geest P. Valproate ethosuximide combination therapy for refractory absence seizures. Arch Neurol 1983; 40:797-802. (Pubitemid 14204322)
56. Leach JP, Brodie MJ. Synergism with GABA-ergic drugs in refractory epilepsy. Lancet 1994; 343:1650. (Pubitemid 24194842)
57. Stephen LJ, Sills GJ, Brodie MJ. Lamotrigine and topiramate may be a useful combination. Lancet 1998; 351:958-959. (Pubitemid 28138476)
58. Brodie MJ, Mumford JP. Double-blind substitution of vigabatrin and valproate in carbamazepine-resistant partial epilepsy. Epilepsy Res 1999; 34:199-205. (Pubitemid 29155491)
59. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2005; 61:246-255.
60. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2003; 2:347-356. (Pubitemid 38352562)
61. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2003; 2:473-481. (Pubitemid 36876104)
62. Pack A. Bone health in people with epilepsy: is it impaired and what are the risk factors? Seizure 2008; 17:181-186.
63. Mintzer S, Mattson RH. Should enzyme-inducing antiepileptic drugs be considered first-line agents? Epilepsia 2009; 50 (suppl 8):42-50.
64. Morrell MJ, Flynn KL, Done S, et al. Sexual dysfunction, sex steroid hormone abnormalities and depression in women with epilepsy treated with antiepilepitc drugs. Epilepsy Behav 2005; 6:360-365. (Pubitemid 40468425)
65. Verrotti A, Loiacono G, Laus M, et al. Hormonal and reproductive disturbances in epileptic male patients: emerging issues. Reprod Toxicol 2011; 31:517-527.
66. Stephen LJ. Drug treatment of epilepsy in elderly people. Focus on valproic acid. Drugs Aging 2003; 20:141-152. (Pubitemid 36246296)
67. Burakgazi E, Harden C, Kelly JJ. Contraception for women with epilepsy. Rev Neurol Dis 2009; 6:E62-E67.
68. Stephen LJ, Brodie MJ. Epilepsy in elderly people. Lancet 2000; 355:1441-1446. (Pubitemid 30215972)
69. Brodie MJ, Stephen LJ. Outcomes in elderly patients with newly diagnosed and treated epilepsy. Int Rev Neurobiol 2007; 81:254-263.
70. Brodie MJ, Elder AT, Kwan P. Epilepsy in later life. Lancet Neurol 2009; 8:1019-1030.
71. Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of antiepileptic drugs. N Engl J Med 2001; 344:1132-1138.
72. Tomson T, Perucca E, Battino D. Navigating toward fetal and maternal health: the challenge of treating epilepsy in pregnancy. Epilepsia 2004; 45:1171-1175. (Pubitemid 39350328)
73. Tomson T, Battino D, Bonizzoni E, et al. For the EURAP study group. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011; 10:609-617.
74. Meador K, Baker G, Browning N, et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 2009; 360:1597-1605.
75. Sillanpää M, Jalava M, Kaleva O, Shinnar S. Long-term prognosis of seizures with onset in childhood. N Engl J Med 1998; 338:1715-1722. (Pubitemid 28268587)
76. Hannah JA, Brodie MJ. Epilepsy and learning disabilities: a challenge for the next millennium? Seizure 1998; 7:3-13. (Pubitemid 28121944)
77. Patsalos P, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs: best practice guidelines for therapeutic drug monitoring: a position paper by the subcom-mission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49:1239-1276. (Pubitemid 351991390)
78. Brodie MJ, Kwan P. Staged approach to epilepsy management. Neurology 2002; 58 (suppl 5):S2-S8. (Pubitemid 34415365)
79. Schiller Y, Najjar Y. Quantifying response to antiepileptic drugs: effect of past treatment history. Neurology 2008; 70:54-65.